Frontlight ResearchEarly access
Not yet recruitingPhase 1
A study to assess the safety of ARGX-118 in healthy adults and adults with Allergic Bronchopulmonary Aspergillosis (ABPA)
Key facts
- Who runs it
- Argenx
- Where
- Belgium2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 112 people, planned
- Started
- 17 Nov 2026
- Expected to end
- 15 May 2029
- Type of study
- Interventional
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Allergic bronchopulmonary aspergillosis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from 2026-525870-20-00, who can take part
- Record updated
- 18 November 2026